Document Detail

Stent thrombosis: incidence, predictors and new technologies.
Jump to Full Text
MedLine Citation:
PMID:  22577541     Owner:  NLM     Status:  In-Data-Review    
Some concerns have been raised regarding the risk of late and very late stent thrombosis (ST) following drug-eluting stent implantation. Despite remaining an uncommon complication of percutaneous coronary intervention, when ST occurs, it can be catastrophic to the individual, commonly presenting as acute ST elevation myocardial infarction or sudden cardiac death. The incidence and predictors of ST have been reported in the literature and the role of dual antiplatelet therapies in the avoidance of such a complication remains vital. Ongoing studies are assessing the role of these therapies including platelet reactivity testing, genetic testing and optimum duration of therapy. In addition, newer polymer-free and bioabsorbable stents are under investigation in the quest to potentially minimise the risk of ST.
Gill Louise Buchanan; Sandeep Basavarajaiah; Alaide Chieffo
Publication Detail:
Type:  Journal Article     Date:  2012-03-11
Journal Detail:
Title:  Thrombosis     Volume:  2012     ISSN:  2090-1496     ISO Abbreviation:  Thrombosis     Publication Date:  2012  
Date Detail:
Created Date:  2012-05-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101566937     Medline TA:  Thrombosis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  956962     Citation Subset:  -    
Interventional Cardiology Unit, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Thrombosis
Journal ID (iso-abbrev): Thrombosis
Journal ID (publisher-id): THROMB
ISSN: 2090-1488
ISSN: 2090-1496
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2012 Gill Louise Buchanan et al.
Received Day: 1 Month: 11 Year: 2011
Accepted Day: 20 Month: 12 Year: 2011
Print publication date: Year: 2012
Electronic publication date: Day: 11 Month: 3 Year: 2012
Volume: 2012E-location ID: 956962
ID: 3329679
PubMed Id: 22577541
DOI: 10.1155/2012/956962

Stent Thrombosis: Incidence, Predictors and New Technologies
Gill Louise Buchanan
Sandeep Basavarajaiah
Alaide Chieffo*
Interventional Cardiology Unit, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
Correspondence: *Alaide Chieffo:
[other] Academic Editor: Matthew J. Price

1. Introduction

Drug-eluting stents (DES) were introduced into clinical practice in order to reduce the rates of restenosis observed with bare metal stents (BMS) for the treatment of coronary artery disease [16]. However, despite the promising results, some concerns have been raised regarding the potential increased risk of late and very late stent thrombosis (ST) following DES implantation. This is felt to be a consequence of delayed endothelialization [7, 8]. The problem was first highlighted during the 2006 European Society of Cardiology and World Congress of Cardiology Meeting in Barcelona, Spain, when the results of two independent meta-analyses were presented demonstrating a higher mortality with DES [9]. This rapidly became known as the “ESC Firestorm,” and, following this, an abundance of data from both randomized clinical trials and multicenter registries have suggested an increased risk of late and very late ST with the use of DES.

ST is a rare but usually catastrophic event, leading to acute vessel closure, frequently associated with ST elevation myocardial infarction (STEMI) or sudden cardiac death. This paper aims to review the current data regarding ST, the underlying causes and methods to reduce the risk. In addition, there is an emphasis on the importance of dual antiplatelet therapy (DAPT) and newer technologies under development, which may in time lead to a vast reduction in the incidence of ST.

2. Definition of Stent Thrombosis according to the Academic Research Consortium

In an attempt to standardize the definition of ST, the Academic Research Consortium (ARC) was formed in 2007, proposing the criteria illustrated in Table 1 [10]. Additionally, the timing of ST can be classified as acute (<24 hours post procedure), early (24 hours to 30 days post procedure), late (31 days to one year post procedure) and very late (>one year post procedure).

3. Incidence of Stent Thrombosis

The actual incidence of ST reported in the literature depends on the duration of follow-up utilized. During the early BMS era, ST was demonstrated to be as high as 20.0% [11]. Following this, advances in the field of interventional cardiology, including high pressure post dilatation and importantly, the addition of ticlopidine to aspirin, led to a significant decrease in the occurrence of ST [12, 13]. It was observed that ST in BMS was uncommon after 30 days, due to complete endothelialization within this time [14], which was supported by a pooled analysis of a multicenter trial, when over 80.0% of angiographically confirmed ST occurred within the first 2 days of the procedure [15].

Similarly, most cases of ST occurring with DES occur within 30 days of the procedure. In the Dutch ST registry of over 21,000 patients who were treated with BMS and DES, the majority of ST cases (>70.0%) were seen within the first month, with a cumulative incidence of definite ST of 2.1% over 3 years [16]. There were no differences demonstrated in the incidence of ST between BMS and DES. A further study by the Bern-Rotterdam group, which assessed 8,146 patients treated with DES (paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES)), reported a cumulative incidence of ST of 3.3% at 3 years. Moreover, the annual incidence of ST in this study was 0.5% [17]. Conversely, a study by a Japanese group (the J-Cypher registry) reported a lower incidence following SES implantation of definite ST at 0.8% over 2 years follow-up [18]. Furthermore, a comprehensive meta-analysis including 9,471 patients from 22 randomized trials, demonstrated no differences in overall mortality (Hazard Ratio (HR) 0.97; 95% Confidence Interval (CI) 0.81–1.15; P = 0.72) or myocardial infarction (MI) (HR 0.95; 95% CI 0.79–1.13; P = 0.54) with DES compared with BMS. In the observational studies arm of this paper, amongst 182,901 patients in 34 studies, there were significant reductions in mortality (HR 0.78; 95% CI 0.71–0.86) and MI (HR 0.87; 95% CI 0.78–0.97) with DES [19]. A further meta-analysis of 13 randomized trials (7,352 patients) demonstrated that there was no increase in ST with DES (RR 0.97; 95% CI 0.73–1.28) over 2 years [20].

Most of the earlier data in DES is obtained from the first generation DES, with the newer second generation DES thought to pose less risk. Studies evaluating their effectiveness over first generation DES have reported few cases of ST. Table 2 illustrates the incidence of ST in clinical trials of second generation DES. The trial “Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with de Novo Coronary Artery Lesions” (SPIRIT IV), which evaluated the results of everolimus-eluting stents (EES) versus PES, reported ST in only 0.3% of EES patients in the first year compared with 0.8% of PES patients [21]. In the trial “A trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice” (COMPARE) which randomized 1,800 patients to EES or PES, the incidence of ST at one year was 1.0% following EES as compared with 3.0% in the PES group [22]. In addition, longer-term follow-up to 3 years showed no statistical difference in the occurrence of ST (EES 1.2% versus SES 1.7%) [23]. Similarly, the ENDEAVOR trials which evaluated the Zotarolimus-eluting stent (ZES) reported a significantly lower incidence of ST compared to first generation DES [2428]. Furthermore, the RESOLUTE all-comers trial showed the rate of ST was lower with EES compared with ZES (0.3% versus 1.2%; P = 0.01) [29]. Additionally, a multicenter registry of 4,768 patients has been reported, which specifically assessed ST of second generation DES (EES and ZES). This demonstrated a cumulative incidence of definite ST in 1.0% of patients at 2 years follow-up. The incremental rate of ST from the first year to the second year was 0.25% [30]. Recently, data has shown no occurrence of very late ST at 3 years in 102 patients undergoing primary angioplasty for STEMI [31].

4. Class Effect

From the available data, it may be inferred that there is a class effect between the different drugs eluted from the permanent polymer stents. In a meta-analysis of 18,023 patients from randomized trials, there was an increased risk of definite late ST with PES versus SES (HR 1.85; 95% CI 1.02–3.85; P = 0.041) [7], which was also shown in other registry studies [34, 35]. Conversely, the “Sirolimus Eluting Stent compared with Paclitaxel Eluting Stent for Coronary Revascularization” (SIRTAX) trial showed no difference between SES and PES (resp., 4.6% versus 4.1%; P = 0.74) at 5 years follow-up [36]. Again, although ST is thought to be lower with the second generation “limus” family of drugs than PES [21, 22], no randomized studies have been adequately powered to assess ST; therefore, further data in this field is awaited.

5. Prognosis Following Stent Thrombosis

Many patients with ST present either as sudden cardiac death or as an acute STEMI. Those individuals who survive the initial event are known to have a poor prognosis [37]. It is important to emphasize that the case fatality rate in those individuals suffering a ST has been demonstrated to be as high as 45.0% in some series [8, 15, 16, 3840]. A study of 431 patients with angiographically confirmed definite ST demonstrated almost one in 5 patients with one definite ST experienced another ST at follow-up, showing the high-risk nature following the initial event [16].

Furthermore, a study of 985 patients who underwent primary angioplasty for STEMI, which included 102 patients with definite ST, demonstrated a higher occurrence of in-hospital death or recurrent MI in those presenting with ST rather than STEMI secondary to a de novo lesion (12.7% versus 7.4%; P = 0.05) [41]. However, of note, these patients had a higher proportion of comorbidities, including diabetes mellitus, chronic kidney disease and lower left ventricular ejection fraction which may have contributed to the difference in outcomes. Additionally, in those with STEMI secondary to ST, there was a larger thrombus burden, more frequent distal embolization and less successful results from PCI [16, 42].

6. Predictors of Stent Thrombosis

In general, ST occurs more frequently in complex patients with complex lesions, for example, acute coronary syndromes, diabetes mellitus, chronic kidney disease, small vessels and multiple stents, including bifurcation lesions and chronic total occlusion [8, 43, 44]. A summary of the underlying patient, lesion and procedural characteristics which are predictors of ST are illustrated in Table 3.

When a ST develops acutely, it is generally due to procedural-related factors, such as incomplete stent expansion, residual edge dissection, the presence of thrombus and reduced TIMI (Thrombolysis In Myocardial Infarction) flow grade [8, 16, 17, 45]. Figure 1 demonstrates a case of acute ST which occurred in a patient following EES for a chronic total occlusion. The commonest reason for subacute and late ST is the discontinuation of DAPT, which will be discussed in more detail in a later section. Notably, risk factors for the development of very late ST are not so well defined. One possible explanation for such late occurrence is incomplete neointimal coverage as a result of delayed arterial healing, ongoing vessel wall inflammation and late acquired stent malapposition [4650]. These phenomena have been observed in patients with DES by real-time imaging studies (angioscopy and optical coherence tomography (OCT)) [47, 4951] and also in some autopsy studies of stented segments in patients with very late ST [46]. Figure 2 demonstrates a definite ST in a patient 18 months following SES implantation and evidence of thrombus on malapposed struts.

7. Procedural Optimization

In view of the clinical course associated with a ST, meticulous attention must be made to reduce the risk from the outset. Risk factors pertaining to the patients' history and lesion characteristics are non-modifiable; however, the procedure can be performed optimally to reduce the incidence of ST. Firstly, it is important to adequately screen the patient, to assess likely adherence to the necessary DAPT regimen, the bleeding risk and the need for any planned surgical procedures in the following 12 months.

The decision then needs to be made regarding the anticoagulation of choice during the procedure. However, this also carries risk, as bleeding complications may not be insignificant. Conventionally, unfractionated heparin has been the anticoagulant of choice in those undergoing PCI, often in combination with a glycoprotein IIb/IIIa inhibitor. In the “Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications” (CADILLAC) trial [52], abciximab use was an independent predictor of no ST (HR 0.27; 95% CI 0.09–0.86; P = 0.026). However, recently bivalirudin, a direct thrombin inhibitor, has become more widespread in use. In the “Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction” (HORIZONS-AMI) trial which randomised 3,602 patients with STEMI undergoing primary angioplasty to heparin plus glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy, acute ST occurred in patients assigned to bivalirudin more frequently (1.4% versus 0.3%; P < 0.001) with conversely ST after 24 hours occurring less frequently (2.8% versus 4.4%, P = 0.02). Notably, there was no difference in the cumulative rates of ST at 2 years between the 2 groups (4.3% versus 4.6%; P = 0.73) [53].

Furthermore, good lesion preparation (considering the use of rotational atherectomy in the presence of severely calcified lesions), use of properly sized stents and postdilatation with non compliant balloons, according to intravascular ultrasound (IVUS) guidance, may help adequate stent expansion and apposition. The space between the stent struts and vessel wall which is present when there is malapposition leads to an area of sluggish flow, which can allow thrombus formation. It is therefore essential to choose the correct stent size and perform effective high pressure postdilatation to reduce this risk. Adequate stent expansion on IVUS has been linked to lower ST at both 30 days and 12 months [54]. This can also ensure there are no remaining edge dissections which may be a nidus for ST.

Newer imaging modalities, such as OCT, may become a useful tool to help assessment of the substrates for ST development, thereby allowing optimization of the initial procedure. As discussed earlier, incomplete stent apposition may be associated with the formation of thrombus; on OCT, thrombus was seen significantly more frequently in struts that were not fully apposed compared to those with good apposition (20.6% versus 2.0%; P < 0.001) [55]. Additionally, it has been shown that DES have a higher rate of uncovered and malapposed struts than BMS with OCT imaging [56].

8. Correlation between Dual Antiplatelet Therapy and Stent Thrombosis

The current recommendations from the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiographic Intervention are that, following DES implantation, patients should receive clopidogrel (or an alternative thienopyridine) in addition to aspirin for a minimum of 12 months, unless there is a high bleeding risk or urgent circumstances arise [57]. The Task Force on myocardial revascularization of the European Society of Cardiology and the European Association for Cardiothoracic Surgery is less specific and state that convincing data exists only for continuation of DAPT up to 6 months [58].

However, the optimal duration after DES implantation remains unknown. The discontinuation of DAPT was the most powerful predictor of ST during the first 6 months following stent implantation in a cohort of over 3,000 patients (HR 13.74; 95% CI 4.04–46.68; P < 0.001) [59]. This was confirmed by a study by Schulz et al. in over 6,000 patients with 4-years follow up [60]. Furthermore, it has been demonstrated that ST occurred in 29.0% of patients who prematurely discontinued DAPT [8]. Conversely, the Bern/Rotterdam registry of over 8,000 patients demonstrated no differences in those treated with clopidogrel for 12 months following DES implantation compared with those treated for only 3–6 months.

Alternatively, it has been suggested that patients treated with clopidogrel for 24 months had improved cumulative survival compared to those treated for 12 months [61]. However, it has been shown in a randomized trial of 2,701 patients who were free of major adverse cardiovascular and cerebrovascular events (MACCE) and major bleeding events for 12 months alter PCI receiving 12 versus 24 months of clopidogrel that the cumulative occurrence of definite ST at 24 months after DES was identical in patients who continued clopidogrel until 24 months (0.4% versus 0.4%; P = 0.76) [62]. The “PROlonging Dual-antiplatelet treatment after Grading stent-Induced hyperplasia” [63] (PRODIGY) study was presented at the European Society of Cardiology Scientific Congress, Paris, 2011 which randomized 2,013 patients on an intention-to-stent basis to EES (n = 501), PES (n = 505), ZES (n = 502), or BMS (n = 505). After 30 days, 1,970 were eligible for randomization to either 6 months DAPT (n = 983) or 24 months DAPT (n = 987) and followed up for 2 years. This showed no benefit of prolonged DAPT in the incidence of ischemic events at the cost of an increased risk of major bleeding (HR 2.17; 95% CI 1.44–3.22; P = 0.00018). The optimal duration is currently being assessed in a number of randomized trials illustrated in Table 4.

A number of factors have been thought to be implicated in the development of ST including clopidogrel resistance, hypersensitivity to the stent polymer, drug interactions and the discontinuation of clopidogrel within the first 6 months [59]. The measurement of platelet function on DAPT can enable those patients at highest risk to be identified [6668], as it is known individual responses to clopidogrel vary significantly [69]. One quarter of individuals may be resistant to the platelet-inhibiting effects of clopidogrel [70, 71]. A recent meta-analysis of over 3,000 patients demonstrated that high on treatment platelet reactivity tested by the VerifyNow assay (Accumetrics, San Diego, California, USA), defined as a P2YC12 Reaction Unit (PRU) of greater than or equal to 230, was associated with ST (HR 3.11; 95% CI 1.50–6.46; P = 0.002) [72]. Moreover, Parodi et al. demonstrated in 1,789 patients undergoing PCI who had platelet reactivity prospectively assessed using light transmittance aggregometry that a high residual platelet reactivity (≥70% platelet aggregation) led to a higher incidence of ST (6.1% versus 2.9%; P = 0.01) [73]. However, even if we are aware of this, no benefit was shown in the “Gauging Responsiveness With a VerifyNow Assay: Impact on Thrombosis and Safety” (GRAVITAS) trial following double dose clopidogrel if there was high on treatment platelet reactivity [74]. In this study, the composite rate of cardiovascular death, MI, or ST was low in both groups (2.3%) at 6 months. However, it is important to note that less than half of patients randomized to clopidogrel 150 mg achieved appropriate variability in antiplatelet response, which may have contributed to the lack of observed clinical effect. In addition, due to the lower than expected event rates, the study was underpowered to detect the clinical efficacy of high-dose clopidogrel. Another randomized study, “Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel” (TRIGGER-PCI), comparing prasugrel to clopidogrel for those with high platelet reactivity was terminated early due to futility as high on clopidogrel platelet reactivity (>208 PRU by VerifyNow) was observed less frequently than expected and there was a low occurrence of the primary endpoint of cardiac death or MI. There are a number of ongoing studies which aim to assess the utilization of platelet reactivity testing and optimization of DAPT following PCI, which are illustrated in Table 5.

Clopidogrel is a prodrug which requires conversion to an active metabolite to provide its effects and resistance can be due to a genetic variation in one of the cytochrome P450 hepatic enzymes necessary for this, particularly the CYP2C19 allele [75]. Patients with polymorphisms in this gene, which accounts for only 5–12% of clopidogrel response variability [76, 77], have more adverse clinical events following PCI. [78, 79]. Indeed, this gene has been independently shown to be associated with early ST [80]. Despite this, currently genetic testing is not widely utilized in patients requiring stent implantation; however, the “Escalating Clopidogrel by Involving a Genetic Strategy—Thrombolysis In Myocardial Infarction 56” (ELEVATE-TIMI) study was recently reported [81]. The aim of this study was to assess whether higher doses of clopidogrel (up to 300 mg) improved responses in the setting of loss of function CYP2C19 genotypes. The genotypes of 333 patients with stable coronary artery disease were established, and it was shown that a dose of 225 mg clopidogrel daily in CYP2C19 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75 mg dose in non-carriers. However, in homozygotes, doses of even 300 mg did not result in comparable degrees of platelet inhibition. A number of studies are currently ongoing to further assess the role of CYP2C19 pharmacogenomics (Table 6). Notably, the US Food and Drug Administration has added a box warning to clopidogrel about the reduced effectiveness in those patients who are poor metabolizers of the drug.

If a patient develops ST while fully compliant with DAPT, then consideration should be given to the modification of the drug regimen. Newer antiplatelet agents, including prasugrel [82] and ticagrelor [83], are now available which have been shown to be more potent, with a consequent reduction in ST [84, 85]. Non responders to clopidogrel also respond well to these newer agents [86, 87]. In patients with acute coronary syndromes, the rates of ST have been reduced by substituting clopidogrel with these drugs, at the risk of increased bleeding [88, 89]. There is also the option of adding in therapy such as cilostazol, a phosphodiesterase inhibitor [90]. This has been shown in a registry study of 3,099 patients to reduce the risk of ST at 12 months as compared to DAPT only (HR 0.136; 95% CI 0.035–0.521; P = 0.0036) [91], with no increase in bleeding complications. However, most studies of cilostazol have been performed in Asians and have not been validated in the Western population.

Finally, drug interactions from other hepatic enzyme inhibitors can result in reduced effectiveness of clopidogrel. Importantly, in recent years, there has been concern regarding the use of concomitant proton pump inhibitors (PPIs) with clopidogrel [92]. However, the “Clopidogrel with or without omeprazole in coronary artery disease” (COGENT) trial which randomly assigned 3,873 patients on DAPT to omeprazole or placebo demonstrated no apparent cardiovascular interaction between the drugs [93]. However, this study was terminated early and therefore was underpowered for the endpoint. The American Heart Association guidelines do not prohibit the use of PPIs, yet highlight the potential risks and benefits of coadministering with clopidogrel [94]. Ongoing studies are assessing the role of CYP2C19 in the drug interaction between clopidogrel and PPIs: the “Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects” (SPICE) trial and the Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects Study.

9. Impact of New Technologies

Currently, there is much interest in the development of new technologies to improve safety outcomes, including a reduction in ST. It has been known for a number of years that durable polymers can cause local arterial injury [95]. Non erodible polymers provoke chronic eosinophilic infiltration within the arterial wall, suggestive of hypersensitivity reactions [96, 97]. Concerns regarding the effects of these polymers had led to the design of stents with either biodegradable polymers or indeed no polymers, which are illustrated in Table 7.

The “Limus Eluted from A Durable versus ERodable Stent coating” (LEADERS) trial randomized 1,707 patients to either SES or biolimus A9-eluting stents (BES). The latter stent elutes biolimus from a polylactide biodegradable polymer applied to the abluminal surface of the stent which is fully metabolized within 6–9 months. At 3 years follow up, the rate of definite ST was 2.2% for the BES and 2.9% for the SES (HR 0.78; 95% CI 0.43–1.43; P = 0.43). However, interestingly, ST increased at a lower rate of 0.2% from one to 3 years for the BES compared with 0.9% for the SES. In addition, patients who had stopped DAPT did not appear to have any additional events at 3 years, with conversely in the SES group, there were development of events [98]. Furthermore, this may be explained by an OCT substudy of the LEADERS trial which demonstrated that BES had better strut coverage at 9 months than SES [99].

Further stents with biodegradable polymers are being developed and are showing promising results in early trials. The Biofreedom stent (Biosensors, Morges, Switzerland), which again is a BES, has demonstrated minimal delayed arterial healing [100]. Additionally, the Synergy stent (Boston Scientific, Natick, MA, USA) which has a bioabsorbable polymer and everolimus drug combination has recruited patients to the EVOLVE study (non-inferiority trial to assess the safety and performance of the evolution coronary stent), and the results are awaited. Finally, the CRE8 (CID, Saluggia, Italy) stent has recently gained CE mark. This is a unique polymer free abluminal reservoir technology together with a new amphilimus formulation which allows controlled and targeted drug elution to the artery. The results of the “International Randomized Comparison between DES Limus Carbostent and Taxus Drug Eluting Stents in the Treatment of De Novo Coronary Lesions” (NEXT) trial were presented at EuroPCR, Paris, France, in 2011 which demonstrated no ST at 180 days.

More recently, completely bioabsorbable stents have been developed to allow complete stent resorption, arterial healing and restoration of normal vascular function. As stent struts theoretically disappear, issues related to late persistent strut malapposition and chronically uncovered struts, including ST, become irrelevant. Additionally, there is elimination of chronic sources of vessel irritation and inflammation which could potentially reduce the need for prolonged DAPT. The “Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System in the Treatment of Patients with Single De Novo Coronary Artery Lesions” (ABSORB) trial was a prospective multicenter, open-label, first-in-man study that assessed the bioabsorbable polymer stent in 30 patients. This has shown no cases of ST at 4 years follow up [101]. The results of the second cohort of the ABSORB trial with the second generation bioabsorbable stent have demonstrated no cardiovascular death at 12 months follow-up [102]. Currently, patients are being recruited for ABSORB Extend which aims to recruit 1,000 patients and follow up for the occurrence of ST. There are several bioabsorbable stents in development and in clinical trials. The REVA stent (REVA medical Inc., San Diego, CA, USA) coated with paclitaxel and the Bioabsorbable Therapeutics stent (Bioabsorbable Therapeutics Inc., Menlo Park, CA, USA) coated with sirolimus are currently being tested.

10. Conclusions

The occurrence of a ST is rare, however, remains one of the most feared complications following PCI, due to the potential catastrophic consequences. There are a number of factors that may lead to the development of a ST and it is essential that we optimize PCI technique and importantly DAPT regimens in all patients undergoing PCI. Newer stents are being developed at rapid rates, and future large-scale randomized trials may help in the decision making regarding these issues in an aim to reduce this dramatic event.

Conflict of Interests

None of the authors has any conflict of interests to disclose in relation to this paper.

1. Moses JW,Leon MB,Popma JJ,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary arteryNew England Journal of MedicineYear: 2003349141315132314523139
2. Morice MC,Serruys PW,Sousa JE,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularizationNew England Journal of MedicineYear: 2002346231773178012050336
3. Cutlip DE,Chauhan MS,Baim DS,et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trialsJournal of the American College of CardiologyYear: 200240122082208912505217
4. Roiron C,Sanchez P,Bouzamondo A,Lechat P,Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trialsHeartYear: 200692564164916216853
5. Williams DO,Abbott JD,Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover RegistryCirculationYear: 2006114202154216217060386
6. Stone GW,Ellis SG,Cannon L,et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trialJournal of the American Medical AssociationYear: 2005294101215122316160130
7. Stettler C,Wandel S,Allemann S,et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysisLancetYear: 2007370959193794817869634
8. Iakovou I,Schmidt T,Bonizzoni E,et al. Incidence, predictors and outcome of thrombosis after succesful implantation of drug-eluting stentsJournal of the American Medical AssociationYear: 2005293172126213015870416
9. Cook S,Meier B. Have we been misled by the ESC DES firestorm?EuroInterventionYear: 20083553553719608475
10. Cutlip DE,Windecker S,Mehran R,et al. Clinical end points in coronary stent trials: a case for standardized definitionsCirculationYear: 2007115172344235117470709
11. Serruys PW,Strauss BH,Beatt KJ,et al. Angiographic follow-up after placement of a self-expanding coronary-artery stentNew England Journal of MedicineYear: 1991324113171984159
12. Cutlip DE,Leon MB,Ho KK,et al. Acute and nine-month clinical outcomes after "suboptimal" coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registryJournal of the American College of CardiologyYear: 199934369870610483950
13. Colombo A,Hall P,Nakamura S,et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidanceCirculationYear: 1995916167616887882474
14. Awata M,Kotani J,Uematsu M,et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stentsCirculationYear: 2007116891091617684153
15. Cutlip DE,Baim DS,Ho KK,et al. Stent thrombosis in the modern Era: a pooled analysis of multicenter coronary stent clinical trialsCirculationYear: 2001103151967197111306525
16. van Werkum JW,Heestermans AA,de Korte FI,et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 casesCirculationYear: 2009119682883419188507
17. Wenaweser P,Daemen J,Zwahlen M,et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort studyJournal of the American College of CardiologyYear: 200852141134114018804739
18. Kimura T,Morimoto T,Nakagawa Y,et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantationCirculationYear: 2009119798799519204304
19. Kirtane AJ,Gupta A,Iyengar S,et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studiesCirculationYear: 2009119253198320619528338
20. Brar SS,Leon MB,Stone GW,et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysisJournal of the American College of CardiologyYear: 200953181677168919406344
21. Stone GW,Rizvi A,Sudhir K,et al. Randomized comparison of everolimus- and paclitaxel-eluting stents: 2-year follow-up from the SPIRIT (clinical evaluation of the XIENCE v everolimus eluting coronary stent system) IV trialJournal of the American College of CardiologyYear: 2011581192521514084
22. Kedhi E,Joesoef KS,McFadden E,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trialThe LancetYear: 20103759710201209
23. Byrne RA,Kastrati A,Massberg S,et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trialJournal of the American College of CardiologyYear: 201158131325133121920260
24. Leon MB,Mauri L,Popma JJ,et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trialJournal of the American College of CardiologyYear: 201055654355420152559
25. Meredith IT,Ormiston J,Whitbourn R,Kay IP,Muller D,Cutlip DE. Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human studyCatheterization and Cardiovascular InterventionsYear: 200974798999519859958
26. Fajadet J,Wijns W,Laarman GJ,et al. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trialCirculationYear: 2006114879880616908773
27. Kandzari DE,Leon MB,Popma JJ,et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trialJournal of the American College of CardiologyYear: 200648122440244717174180
28. Eisenstein EL,Leon MB,Kandzari DE,et al. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)JACC: Cardiovascular InterventionsYear: 20092121199120720129546
29. Silber S,Windecker S,Vranckx P,Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trialThe LancetYear: 2011377977312411247
30. de la Torre Hernndez JM,Alfonso F,Gimeno F,et al. Thrombosis of second-generation drug-eluting stents in real practice: results from the multicenter Spanish registry ESTROFA-2 (estudio espaol sobre trombosis de stents farmacoactivos de segunda generacion-2)JACC: Cardiovascular InterventionsYear: 20103991191920850089
31. Shelton RJ,Chitkara K,Singh R,et al. Three-year clinical outcome with the endeavor zotarolimus-eluting stent in primary percutaneous coronary intervention for st elevation myocardial infarction: the Endeavor Primary PCI Study (E-PPCI)Journal of Interventional CardiologyYear: 201124654254821883474
32. Rasmussen K,Maeng M,Kaltoft A,et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trialThe LancetYear: 2010375972010901099
33. Park DW,Kim YH,Yun SC,et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trialJournal of the American College of CardiologyYear: 201056151187119520883925
34. Daemen J,Wenaweser P,Tsuchida K,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort studyLancetYear: 2007369956266767817321312
35. Kaltoft A,Jensen LO,Maeng M,et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry)Journal of the American College of CardiologyYear: 200953865866419232897
36. Räber L,Wohlwend L,Wigger M,et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trialCirculationYear: 2011123242819282821646500
37. Burzotta F,Parma A,Pristipino C,et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST studyEuropean Heart JournalYear: 200829243011302118987096
38. Kuchulakanti PK,Chu WW,Torguson R,et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stentsCirculationYear: 200611381108111316490815
39. Kimura T,Morimoto T,Kozuma K,et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the registry of stent thrombosis for review and reevaluation (RESTART)CirculationYear: 20101221526120566955
40. Mauri L,Hsieh WH,Massaro JM,Ho KK,D'Agostino R,Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stentsNew England Journal of MedicineYear: 2007356101020102917296821
41. Belle L,Mahmoudi M,Delhaye C,et al. Do patients with drug-eluting stent thrombosis have a similar prognosis to patients presenting with ST-Elevation myocardial infarction of de novo lesions?Journal of Interventional CardiologyYear: 201124432032521535151
42. Sianos G,Papafaklis MI,Daemen J,et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burdenJournal of the American College of CardiologyYear: 200750757358317692740
43. Holmes DR Jr.,Kereiakes DJ,Garg S,et al. Stent thrombosisJournal of the American College of CardiologyYear: 201056171357136520946992
44. Windecker S,Meier B. Late coronary stent thrombosisCirculationYear: 2007116171952196517965406
45. Cheneau E,Leborgne L,Mintz GS,et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound studyCirculationYear: 20031081434712821553
46. Finn AV,Joner M,Nakazawa G,et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelializationCirculationYear: 2007115182435244117438147
47. Joner M,Finn AV,Farb A,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic riskJournal of the American College of CardiologyYear: 200648119320216814667
48. Matsumoto D,Shite J,Shinke T,et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomographyEuropean Heart JournalYear: 200728896196717135281
49. Kang S-J,Mintz GS,Akasaka T,et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantationCirculationYear: 2011123252954296321646494
50. Chen BX,Ma FY,Luo W,et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomographyHeartYear: 200894556657017923466
51. Kim TH,Kim JS,Kim BK,et al. Long-term (>/ = 2) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up resultsInternational Journal of Cardiovascular ImagingYear: 201127687588120978851
52. Dangas G,Aymong ED,Mehran R,et al. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial)American Journal of CardiologyYear: 200494898398815476608
53. Dangas GD,Caixeta A,Mehran R,et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarctionCirculationYear: 2011123161745175621482968
54. Roy P,Steinberg DH,Sushinsky SJ,et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stentsEuropean Heart JournalYear: 200829151851185718550555
55. Ozaki Y,Okumura M,Ismail TF,et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history studyEuropean Heart JournalYear: 201031121470147620363765
56. Guagliumi G,Costa MA,Sirbu V,et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trialCirculationYear: 2011123327428121220730
57. King SB,Smith SC Jr.,Hirshfeld JW Jr.,et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelinesJournal of the American College of CardiologyYear: 200851217220918191745
58. Wijns W,Kolh P,Danchin N,et al. Guidelines on myocardial revascularizationEuropean Heart JournalYear: 201031202501255520802248
59. Airoldi F,Colombo A,Morici N,et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatmentCirculationYear: 2007116774575417664375
60. Schulz S,Schuster T,Mehilli J,et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year periodEuropean Heart JournalYear: 200930222714272119596658
61. Tanzilli G,Greco C,Pelliccia F,et al. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study)American Journal of CardiologyYear: 2009104101357136119892050
62. Park SJ,Park DW,Kim YH,et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stentsNew England Journal of MedicineYear: 2010362151374138220231231
63. Valgimigli M,Campo G,Percoco G,et al. Randomized comparison of 6-versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY)American Heart JournalYear: 2010160580481121095265
64. Byrne RA,Schulz S,Mehilli J,et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: safety and EFficacy of 6 Months Dual Antiplatelet Therapy after Drug-Eluting Stenting (ISAR-SAFE) studyAmerican Heart JournalYear: 20091574620624.e219332187
65. Mauri L,Kereiakes DJ,Normand S-L,et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesionsAmerican Heart JournalYear: 2010160610351041.e121146655
66. Gori AM,Marcucci R,Migliorini A,et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stentsJournal of the American College of CardiologyYear: 200852973473918718420
67. Barragan P,Bouvier J-L,Roquebert P-O,et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylationCatheterization and Cardiovascular InterventionsYear: 200359329530212822144
68. Buonamici P,Marcucci R,Migliorini A,et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosisJournal of the American College of CardiologyYear: 200749242312231717572245
69. Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectivesJournal of the American College of CardiologyYear: 200749141505151617418288
70. Lau WC,Gurbel PA,Watkins PB,et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistanceCirculationYear: 2004109216617114707025
71. Gurbel PA,Bliden KP,Hiatt BL,O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivityCirculationYear: 2003107232908291312796140
72. Brar SS,Ten Berg J,Marcucci R,et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant dataJournal of the American College of CardiologyYear: 201158191945195422032704
73. Parodi G,Marcucci R,Valenti R,et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCIJournal of the American Medical AssociationYear: 2011306111215122321934054
74. Price MJ,Berger PB,Teirstein PS,et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialJournal of the American Medical AssociationYear: 2011305111097110521406646
75. Simon T,Verstuyft C,Mary-Krause M,et al. Genetic determinants of response to clopidogrel and cardiovascular eventsNew England Journal of MedicineYear: 2009360436337519106083
76. Shuldiner AR,O'Connell JR,Bliden KP,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJournal of the American Medical AssociationYear: 2009302884985719706858
77. Hochholzer W,Trenk D,Fromm MF,et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placementJournal of the American College of CardiologyYear: 201055222427243420510210
78. Holmes DR Jr.,Dehmer GJ,Kaul S,Leifer D,O'Gara PT,Stein CM. ACCF/AHA clinical alert: ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning" a report of the American college of cardiology foundation task force on clinical expert consensus documents and the American heart associationCirculationYear: 2010122553755720585015
79. Bonello L,Tantry US,Marcucci R,et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphateJournal of the American College of CardiologyYear: 2010561291993320828644
80. Cayla G,Hulot J-S,O'Connor SA,et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosisJournal of the American Medical AssociationYear: 2011306161765177422028352
81. Mega JL,Hochholzer W,Frelinger AL III.,et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular diseaseJournal of the American Medical AssociationYear: 2011306202221222822088980
82. Wallentin L,Varenhorst C,James S,et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEuropean Heart JournalYear: 2008291213018055486
83. Gurbel PA,Bliden KP,Butler K,et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET studyCirculationYear: 2009120252577258519923168
84. Wiviott SD,Braunwald E,Angiolillo DJ,et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38CirculationYear: 2008118161626163618757948
85. Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromesNew England Journal of MedicineYear: 2009361111045105719717846
86. Wiviott SD,Trenk D,Frelinger AL,et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trialCirculationYear: 2007116252923293218056526
87. Gurbel PA,Bliden KP,Butler K,et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND studyCirculationYear: 2010121101188119920194878
88. Cannon CP,Harrington RA,James S,et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyThe LancetYear: 20103759711283293
89. Montalescot G,Wiviott SD,Braunwald E,et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialThe LancetYear: 20093739665723731
90. Jeong YH,Lee SW,Choi BR,et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized studyJournal of the American College of CardiologyYear: 200953131101110919324253
91. Lee SW,Park SW,Yun SC,et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry)American Heart JournalYear: 20101592284291.e120152228
92. O'Donoghue ML,Braunwald E,Antman EM,et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsThe LancetYear: 20093749694989997
93. Bhatt DL,Cryer BL,Contant CF,et al. Clopidogrel with or without omeprazole in coronary artery diseaseNew England Journal of MedicineYear: 2010363201909191720925534
94. Wright RS,Anderson JL,Adams CD,et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for CardiovascularJournal of the American College of CardiologyYear: 201157191920195921450428
95. Van der Giessen WJ,Lincoff AM,Schwartz RS,et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteriesCirculationYear: 1996947169016978840862
96. Nakazawa G,Otsuka F,Nakano M,et al. The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stentsJournal of the American College of CardiologyYear: 201157111314132221376502
97. Lüscher TF,Steffel J,Eberli FR,et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implicationsCirculationYear: 200711581051105817325255
98. Wykrzykowska J,Serruys P,Buszman P,et al. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS)EuroInterventionYear: 20117778979522027687
99. Barlis P,Regar E,Serruys PW,et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-studyEuropean Heart JournalYear: 201031216517619889649
100. Tada N,Virmani R,Grant G,et al. Polymer-free Biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine modelCirculation: Cardiovascular InterventionsYear: 20103217418320407114
101. Dudek D,Onuma Y,Ormiston JA,et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with denovo coronary artery disease: the ABSORB trialEuroInterventionYear: 2011791060106121959320
102. Serruys PW,Onuma Y,Dudek D,et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de Novo Coronary Artery stenosis: 12-month clinical and imaging outcomesJournal of the American College of CardiologyYear: 201158151578158821958884

Article Categories:
  • Review Article

Previous Document:  Lack of Association between Recurrent Pregnancy Loss and Inherited Thrombophilia in a Group of Colom...
Next Document:  Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones.